Ipatasertib, an oral AKT inhibitor, in combination with carboplatin exhibits anti-proliferative effects in uterine serous carcinoma

Ipatasertib, an oral AKT inhibitor, in combination with carboplatin exhibits anti-proliferative effects in uterine serous carcinoma

AbstractPurpose Uterine serous carcinoma (USC) exhibits worse survival rates compared to the endometrioid subtype, and there is currently no effective treatment options for recurrence of this disease after platinum-based chemotherapy. Activation of PIK3CA/AKT/mTOR signaling pathway is a common biolo...

Full description

Bibliographic Details
Main Authors: Wesley C. Burkett, Ziyi Zhao, Meredith A. Newton, Wenchuan Sun, Boer Deng, Angeles Alvarez Secord, Chunxiao Zhou, Victoria Bae-Jump
Format: Article
Language:English
Published: Taylor & Francis Group 2023-12-01
Series:Annals of Medicine
Subjects:
Ipatasertib
apoptosis
invasion
synergy
carboplatin
uterine serous carcinoma
Online Access:https://www.tandfonline.com/doi/10.1080/07853890.2023.2177883

Internet

https://www.tandfonline.com/doi/10.1080/07853890.2023.2177883

Similar Items